Skip to main content Skip to search Skip to main navigation

EMA: Public Consultation of Annexes to ICH Q3C and VICH GL18 on Residual Solvents

The European Medicines Agency (EMA) has published revised annexes to the ICH Q3C guideline (“Impurities: Guideline for Residual Solvents”) and the corresponding veterinary guideline VICH GL18 for public consultation. The commenting period is open until the end of June 2026.

The revision aims primarily to align the annexes with the latest version of the ICH Q3C guideline (up to Revision R9) and to further harmonise requirements between human and veterinary medicinal products. In addition, the update addresses practical challenges and ambiguities observed in regulatory assessment and inspections.

The changes concern Annex I only, while Annex II remains unchanged. A key new feature is the introduction of decision trees, intended to provide structured guidance on the control of residual solvents. These are designed to support consistent decision-making regarding when testing is required, when specifications need to be established, and how appropriate control strategies can be justified.

Furthermore, the revised annex includes more explicit expectations regarding the management of manufacturing changes, such as changes in starting materials, suppliers, or process parameters. In such cases, a more systematic assessment of the impact on residual solvents is required, including, where appropriate, revalidation activities.


Source:

EMA: Annexes to: EMA/CHMP/ICH/82260/2006 - ICH Q3C Guideline on impurities: guideline for residual solvents and EMA/CVMP/VICH/502/1999 - VICH GL18 Impurities: residual solvents in new veterinary medicinal products, active substances and excipients

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

What are the Basic Principles of Organisational Structures?

What are the Basic Principles of Organisational Structures?

Here's the answer:
Read more
Why Nobody Wants ICH Q14 — And Why That’s Exactly the Problem

Why Nobody Wants ICH Q14 — And Why That’s Exactly the Problem

The ICH Guideline Q14 “Analytical Procedure Development” was published in November 2023. This forward-looking and regulatory-savvy document builds upon the content of ICH Q2(R2) “Validation of Analytical Procedures” and incorporates elements from ICH Q8 “Pharmaceutical Development” and ICH Q9(R1) “Quality Risk Management.”
Read more
EU: GMP Annex 19 Updated

EU: GMP Annex 19 Updated

The European Commission has published a revised version of Annex 19 “Reference and Retention Samples”. The update mainly affects requirements for reference and retention samples of parallel imported, parallel distributed and parallel traded medicinal products.
Read more
ANVISA: Expands Recognition of Foreign GMP Authorities

ANVISA: Expands Recognition of Foreign GMP Authorities

Brazilian health authority ANVISA has updated the requirements for the recognition of Equivalent Foreign Regulatory Authorities (AREE) and the administrative procedures for Good Manufacturing Practice (GMP) certification (CBPF) through Normative Instruction IN 451/2026. The aim is to streamline and accelerate regulatory processes.
Read more
EDQM: Guidance on Reporting on Disappearances of Medicinal Products

EDQM: Guidance on Reporting on Disappearances of Medicinal Products

The EDQM has published guidance supporting the implementation of Recommendation CM/Rec(2024)3 on reporting medicinal products that disappear from the legal supply chain due to theft, loss or diversion. The initiative follows a European survey that identified shortcomings in reporting and co-ordination of such incidents.

Read more
Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
Previous
Next